Price Chart

Profile

CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR’s most advanced pipeline candidate, exa-cel, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
URL https://www.crisprtx.com
Investor Relations URL http://ir.crisprtx.com/
HQ State/Province N/A
Sector Healthcare
Industry Biotechnology
Equity Style Mid Cap/Growth
Next Earnings Release Feb. 21, 2024 (est.)
Last Earnings Release Feb. 21, 2024
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A

Profile

CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR’s most advanced pipeline candidate, exa-cel, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
URL https://www.crisprtx.com
Investor Relations URL http://ir.crisprtx.com/
HQ State/Province N/A
Sector Healthcare
Industry Biotechnology
Equity Style Mid Cap/Growth
Next Earnings Release Feb. 21, 2024 (est.)
Last Earnings Release Feb. 21, 2024
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A